Cancer Fighter Biocancell Raises $6M

May 2, 2016 | Israeli cancer treatment drug developer Biocancell announced a $6 million financing round from US investors. Biocancell also announced the recruitment of a US CEO: former Ariad senior VP and chief medical officer Frank Haluska. The company also intends to register for trading on the Nasdaq stock exchange and raise tens of millions of dollars there. The company was founded in 2004 by Prof. Avraham Hochberg, a professor of molecular biology at the Hebrew University in Jerusalem.